Overview

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Salmeterol Xinafoate